https://www.europesays.com/ch/141287/ Roche’s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study #BispecificAntibody #FollicularLymphoma #lenalidomide #lymphoma #OutpatientTreatment #PhaseIII #Roche #SafetyProfile
#follicularlymphoma — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #follicularlymphoma, aggregated by home.social.